Bluebird Bio Jumps After Gilead Buys Peer Kite Pharma


Shares of Bluebird Bio (BLUE) are up 6% in premarket trading to $104.00 after Gilead Sciences (GILD) announced an agreement to acquire Kite Pharma (KITE) for $11.9B or $180 per share.

Juno Therapeutics (JUNO) is up 14% to $35.00 while Cellectis (CLLS) is up 8% to $27.18.
 

Reviews

  • Total Score 0%
User rating: 0.00% ( 0
votes )



Leave a Reply

Your email address will not be published. Required fields are marked *